Physician profile
Cori A Morrison
NPI 1679743728
$1,449.44
in general payments reported to CMS, 2019-2025
28 companies · $87.98 in 2025
The $87.98 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $160 · 2021: $207 · 2022: $113 · 2023: $255 · 2024: $117 · 2025: $87.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $460.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $297.03 | 2019-2023 | |
| Novo Nordisk INC | $154.44 | 2019-2025 | |
| Bioverativ Therapeutics INC. | $110.26 | 2019 | |
| Sobi, INC | $103.09 | 2019-2021 | |
| Global Blood Therapeutics, INC. | $98.52 | 2020-2021 | |
| Servier Pharmaceuticals LLC | $82.98 | 2019-2021 | |
| Pfizer INC. | $69.76 | 2023-2024 | |
| Csl Behring | $61.51 | 2019-2023 | Idelvion |
| Alexion Pharmaceuticals, INC. | $57.73 | 2019-2024 | Ultomiris |
| Eurofins Viracor, LLC | $51.87 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.43 | 2021-2022 | |
| Springworks Therapeutics, INC. | $33.00 | 2025 | Gomekli |
| Y-Mabs Therapeutics, INC. | $30.84 | 2025 | Danyelza |
| Fennec Pharmaceuticals, INC. | $27.91 | 2023 | Pedmark |
| Genetix Biotherapeutics INC | $21.48 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $21.09 | 2024 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Genentech USA, INC. | $20.56 | 2024 | Hemlibra |
| Avanos Medical | $19.99 | 2023 | Enfit |
| Jazz Pharmaceuticals INC. | $19.31 | 2019 | |
| Adaptive Biotechnologies Corporation | $18.28 | 2024 | Clonoseq |
| Btg International INC. | $16.96 | 2023 | |
| Shire North American Group INC | $16.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.52 | 2021 | |
| Seagen INC. | $15.29 | 2023 | Adcetris |
| Medexus Pharma, INC. | $15.00 | 2021 | |
| Duchesnay USA Incorporated | $13.19 | 2019 | |
| Silvergate Pharmaceuticals, INC. | $12.10 | 2019 | |
| Emmaus Medical, INC. | $10.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cori Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.